
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical-stage biopharmaceutical company with a promising pipeline of therapeutic candidates, particularly Seralutinib which targets the underlying causes of PAH, a serious and currently underserved disease. The company is expecting important data from its PROSERA and FRI studies in mid-2021, which could potentially lead to a new drug application for Seralutinib. The company has a strong management team and strategic partnerships in place, and with a valuation of approximately $2.6 billion, presents an attractive investment opportunity with a potential price target of $10.
Bears say
Gossamer Bio is facing multiple challenges in several key areas, causing a negative outlook on the stock. The company's Phase 3 PROSERA data for seralutinib in PAH fell short of expectations, and the management has noted unusual placebo performance in certain regions. Additionally, the company must restructure its existing convertible debt and secure additional financing for commercialization. Furthermore, adjustments to the company's revenue and market models, coupled with an increased valuation discount rate, have led to a decrease in the target price for the stock.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares